1976 Volume 25 Issue 7 Pages 387-391
Bleomycin labelled with 111In was used as a tumor-localizing agent in 36 patients (40 scintigrams), who were suspected or diagnosed having malignant tumor clnically.
All patients were inpatients and outpatients of the Department of Radiology, University of Tokyo.
The regions where clinically suspected malignant disease and where abnormally accumulated on scintigrams were excluded to estimate the normal distribution of 111In-BLM.
All scintigrams were taken 48 hrs after injection of 111In-BLM 2-3 mCi.
The score of normal distribution was as followings: liver 100, mediastinum 54.0, thyroid area 50.0, nasopharynx 48.5, salivary area 42.5, lumbar spine 40.5 and kidneys 30.5.
The large intestine, hip joints, eye area and lung fields were revealed in a few cases.
Compared this study with the previous study on normal distribution of 67Ga-citrate, the score of large intestine was shown 28.5-37 points on 67Ga-citrate scintigrams but it was only 1.5-0 points on 111In-BLM scintigrams.
The kidneys were not app reciated on 67Ga-citrate scintigrams, but its score was 31.5 on 111In-BLM scintigrams. On chest, the heart was not revealed on 67Ga-citrate scintigrams, but its score was 37.5 on 111In-BLM scintigrams.
We conclude that 111In-BLM would be more effective than 67Ga-citrate in detecting malignant tumors which locate in lower abdomen.
